Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Helixmith Co., Ltd
  6. Summary
    A084990   KR7084990001

HELIXMITH CO., LTD

(A084990)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
05/10/2021 05/11/2021 05/12/2021 05/13/2021 05/14/2021 Date
32300 31100 30350 30250 30000 Last
337031 331511 272109 203421 157592 Volume
+2.05% -3.72% -2.41% -0.33% -0.83% Change
Financials
Sales 2021 4,52 B 0,00 B 0,00 B
Net income 2021 - - -
Net cash position 2021 144 B 0,13 B 0,13 B
P/E ratio 2021 -
Yield 2021 -
Sales 2022 4,74 B 0,00 B 0,00 B
Net income 2022 - - -
Net cash position 2022 132 B 0,12 B 0,12 B
P/E ratio 2022 -
Yield 2022 -
Capitalization 1 027 B 911 M 912 M
EV / Sales 2021 196x
EV / Sales 2022 189x
Nbr of Employees 58
Free-Float 90,3%
More Financials
Company
Helixmith Co Ltd, formerly ViroMed Co Ltd, is a Korea-based company mainly engaged in the development and sales of natural medicines and health functional foods. The Company operates its business through two segments. The Natural Products Business segment develops and sells raw materials for functional materials and health functional foods such as Alex, Murphine, and Nimosin. The New Biopharmaceutical Business... 
More about the company
Notations Surperformance© of Helixmith Co., Ltd
Trading Rating : - Investor Rating :
More Ratings
All news about HELIXMITH CO., LTD
2016VIROMEDá : Publishes Results from Critical Limb Ischemia (CLI) Phase II Clinical..
BU
2015VIROMEDá : US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical ..
BU
2015VIROMEDá : dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Show..
BU
More news
News in other languages on HELIXMITH CO., LTD

- No features available -

More news
Chart HELIXMITH CO., LTD
Duration : Period :
Helixmith Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 33 000,00 KRW
Last Close Price 30 000,00 KRW
Spread / Highest target 10,0%
Spread / Average Target 10,0%
Spread / Lowest Target 10,0%
Managers and Directors
NameTitle
Sun-Young Kim Co-Chief Executive Officer & Director
Seung-Shin Yoo Co-Chief Executive Officer & Director
Han-Ik Na Chief Financial Officer & Director
Chas Bountra Independent Director
Jae-Seung Oh Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
HELIXMITH CO., LTD-9.09%911
GILEAD SCIENCES, INC.18.28%85 949
WUXI APPTEC CO., LTD.13.72%57 931
VERTEX PHARMACEUTICALS-8.15%56 197
REGENERON PHARMACEUTICALS7.05%53 499
BIONTECH SE136.47%46 558